Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Mark Geyer, MD

Memorial Sloan Kettering Cancer Center

N/A

Poster(s):

2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes